Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc.verified

TRDA

Price:

$18.8

Market Cap:

$703.50M

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporate...[Read more]

Industry

Biotechnology

IPO Date

2021-10-29

Stock Exchange

NASDAQ

Ticker

TRDA

The Enterprise Value as of November 2024 (TTM) for Entrada Therapeutics, Inc. (TRDA) is 686.76M

According to Entrada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 686.76M. This represents a change of 39.85% compared to the average of 491.07M of the last 4 quarters.

Entrada Therapeutics, Inc. (TRDA) Historical Enterprise Value (quarterly & annually)

How has TRDA Enterprise Value performed in the past?

The mean historical Enterprise Value of Entrada Therapeutics, Inc. over the last ten years is 517.53M. The current 686.76M Enterprise Value has changed 13.17% with respect to the historical average. Over the past ten years (40 quarters), TRDA's Enterprise Value was at its highest in in the September 2024 quarter at 632.53M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

Quarterly (TTM)
Annual

Average

517.53M

Median

499.36M

Minimum

243.50M

Maximum

731.56M

Entrada Therapeutics, Inc. (TRDA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Entrada Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 65.86%

Maximum Annual Enterprise Value = 731.56M

Minimum Annual Increase = -65.67%

Minimum Annual Enterprise Value = 243.50M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023499.36M23.64%
2022403.86M65.86%
2021243.50M-65.67%
2020709.36M-3.03%

Entrada Therapeutics, Inc. (TRDA) Average Enterprise Value

How has TRDA Enterprise Value performed in the past?

The current Enterprise Value of Entrada Therapeutics, Inc. (TRDA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

382.24M

5-year avg

517.53M

10-year avg

517.53M

Entrada Therapeutics, Inc. (TRDA) Enterprise Value vs. Peers

How is TRDA’s Enterprise Value compared to its peers?

Entrada Therapeutics, Inc.’s Enterprise Value is greater than Molecular Partners AG (130.63M), greater than PMV Pharmaceuticals, Inc. (47.77M), greater than Monte Rosa Therapeutics, Inc. (439.72M), greater than Vigil Neuroscience, Inc. (98.69M), greater than Third Harmonic Bio, Inc. (269.19M), greater than Cullinan Oncology, Inc. (630.54M), less than Edgewise Therapeutics, Inc. (3.01B), greater than Rallybio Corporation (17.23M), less than Crinetics Pharmaceuticals, Inc. (4.93B), less than Centessa Pharmaceuticals plc (1.75B), less than Disc Medicine, Inc. (1.74B), greater than Larimar Therapeutics, Inc. (363.34M), greater than PepGen Inc. (120.50M), less than Tyra Biosciences, Inc. (703.47M), less than Pharvaris N.V. (850.00M), less than Eliem Therapeutics, Inc. (0), greater than Genenta Science S.p.A. (119.64M), greater than Opthea Limited (78.68M), greater than Pardes Biosciences, Inc. (514.42M), greater than null (75.90M),

Build a custom stock screener for Entrada Therapeutics, Inc. (TRDA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Entrada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Entrada Therapeutics, Inc. (TRDA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Entrada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Entrada Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Entrada Therapeutics, Inc. (TRDA)?

What is the 3-year average Enterprise Value for Entrada Therapeutics, Inc. (TRDA)?

What is the 5-year average Enterprise Value for Entrada Therapeutics, Inc. (TRDA)?

How does the current Enterprise Value for Entrada Therapeutics, Inc. (TRDA) compare to its historical average?